Metrion Biosciences’ Post

🌟 𝐈𝐧𝐌𝐞𝐝'𝐬 𝐈𝐍𝐌-𝟗𝟎𝟏: 𝐀 𝐍𝐞𝐰 𝐇𝐨𝐩𝐞 𝐟𝐨𝐫 𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫’𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭! 💡 𝗜𝗻 𝗝𝘂𝗹𝘆 𝟮𝟬𝟮𝟰, InMed Pharmaceuticals recently released preclinical data indicating its proprietary, #smallmolecule compound, INM-901, targets multiple #biological pathways associated with #Alzheimer’sdisease. Among the most interesting data from the recent reports, was the ability of its compound to extend the length of #neurites, which may indicate enhanced neuronal functioning in the #brain and the potential to reverse the #damage caused by Alzheimer’s disease. The company was encouraged with these breakthrough preclinical results and will be advancing the development of the INM-901 Alzheimer’s disease program. InMed's preclinical model of Alzheimer's disease, which is well characterised, showed encouraging outcomes in both in vitro and in vivo trials. The study claims that it might encourage neurite growth and extension, or neutogenesis, a crucial aspect of cell-to-cell communication. In in-vivo experiments, INM-901 also revealed decreased neuroinflammation and improved behaviour, memory, and cognitive function. 𝗕𝗿𝗼𝘄𝘀𝗲 𝗮𝘁 𝗼𝘂𝗿 𝗥𝗲𝗹𝗮𝘁𝗲𝗱 𝗥𝗲𝗽𝗼𝗿𝘁 👉:https://bit.ly/46jbV2x #AlzheimersTreatment #InnovativeTherapy #AlzheimersResearch #MultiFactorialApproach #BreakthroughMedicine #NeuroScience #AlzheimersHope #prophecymarketinsights

The moonshot is a fundamental array of new therapeutics. Is monepantel going to be part of this moonshot approach? Can monepantel address one of the underlying mechanism of ALS - dysfunctional autophagy? Follow #PharmAust on its journey to tackle this hideous disease front on. #ALS #ALSStrong #ALSAwareness #MNDAustralia #FightMND #Biotech #Science #Neuroscience #NeurodegenerativeDiseases

Unlocking CNS RNA-based therapeutics using ionizable nanoemulsions: scientific curiosity or real clinical potential? The use of LNPs for targeting complex tissues like the central nervous system remains limited due to poor diffusivity and challenges in overcoming brain barriers. Addressing this critical bottleneck, a quite recent research introduces a "potentially transformative" solution: ionizable nanoemulsions (or iNEs), designed to enhance the delivery and efficacy of RNA-based genetic therapeutics within the CNS. The newly developed iNEs are engineered with a unique combination of C12–200, DOPE, Vitamin E, and DMG-PEG, achieving a formulation that is not only potent but also physiologically compatible. With a particle size under 100 nm and a neutral surface charge, these nanoemulsions exhibited a high RNA loading capacity. Furthermore, the iNEs demonstrated excellent cell viability and transfection efficiency across several cellular models, including neurons, astrocytes, and microglia—key components of the CNS. In a pivotal set of experiments, iNEs loaded with mRNA encoding GFP were administered intra-parenchymally to test their CNS transfection capabilities. The results were striking: the iNEs not only diffused effectively within the brain's complex tissue architecture but also selectively transfected neurons, showcasing their potential to bypass the stringent barriers that typically impede genetic delivery to the brain. By enhancing the diffusivity and targeting capabilities of RNA carriers, ionizable nanoemulsions potentially open new avenues for the treatment of neurological disorders, offering hope for therapies that require precise genetic modifications at the cellular level. Learn more here: https://lnkd.in/eqrcp7vP #Neuroscience #GeneticTherapy #Nanotechnology #Biotechnology #RNAtherapy #InnovativeResearch #DrugDelivery #CNS #BrainHealth #ScientificBreakthrough

In this interview, Drug Target Review's Taylor Mixides met with Michelle Sidor, Director of Neuroscience at Alchemab Therapeutics Ltd, and Iosif (Sifis) Pediaditakis at the Society for Neuroscience meeting to explore neuroscientific research and its pivotal role in steering the industry toward future triumphs. Dr. Sidor highlights the dynamic landscape, emphasizing the significance of staying abreast of research advancements and technological innovations. As we optimize the development of #neuroscience therapeutics, it is great to see other #biotech companies integrate innovative technologies to ensure that they can bring medicines to the right patient at the right time as soon as possible. Learn more: https://lnkd.in/egJKixUk

Our axoCells™ Astrocytes line (ax0704) is designed to fuel robust in vitro models for neurodegenerative disease research and drug discovery. With labs around the world increasingly moving to in vitro models, drug discovery researchers are embracing human iPSC-derived cells to build more human, more functional models for neuroscience. But with many labs still using rat astrocytes for their work (with very long protocols, some even >100 days), we're "supporting the switch" to human iPSCs with our axoCells Astrocytes product that can drive faster, cheaper in vitro workflows. Key highlights of our axoCells Astrocytes product include: • Best price on the market • Derived from fibroblasts taken from a healthy 40-50-year-old male donor • Assay ready in just 48 hours • Express seven key markers of primary human astrocytes including GFAP, AQP4 and S100B and astrocyte-associated markers (EAAT1 and ALDH1L1) with low levels of neuronal progenitor markers including Nestin • Specifically developed for use in powerful in vitro monoculture models and complex co-culture systems for drug discovery Click here to read more about this product line and how you can use axoCells Astrocytes to power robust, physiologically relevant models of Alzheimer’s Disease, Parkinson’s Disease and ALS: https://hubs.la/Q02H3DrG0 Want to explore the details and get a quote? Click here: https://hubs.la/Q02H44NX0 #iPSCs #Astrocytes #AlzheimersDisease #ParkinsonsDisease #ALS #DrugDiscovery

🧠💡 Exciting Insights into Precision Neuroscience and Precision Medicine in CNS Conditions 💊🔬 Delighted to share insights from Dr. Steve Gardner, CEO of PrecisionLife, a leading computational biology company. Dr. Gardner delves into the challenges faced in achieving precision medicine within complex CNS conditions. He highlights the promising advancements in precision neuroscience approaches, illustrating how pharmaceutical companies are reinvesting in the field. Their efforts aim to develop enhanced treatments for neurological and neuropsychiatric diseases, bringing hope to millions worldwide. Stay tuned for groundbreaking developments! #PrecisionMedicine #Neuroscience #PrecisionNeuroscience #CNSConditions #HealthcareInnovation #Pharmaceuticals #Research #PrecisionLife #NeuropsychiatricDiseases #drugdiscovery Drug Discovery World https://lnkd.in/eXnk58vk

Key Facts: Unexpected Memory Mechanism: Brain inflammation and DNA damage in hippocampal neurons are essential for the formation of long-term memories, facilitated by the TLR9 inflammatory pathway. DNA Damage and Repair: The study found that hippocampal neurons undergo cycles of DNA damage and repair, organizing them into memory assemblies crucial for storing episodic memories. Caution Against Inhibition: While drugs targeting the TLR9 pathway may offer therapeutic potential, their use requires caution due to the pathway’s essential role in memory formation and the risk of genomic instability.

Very interesting paper coming out today from the Christal Sohl lab at San Diego State University in collaboration with Şevin Turcan lab at University of Heidelberg. They show that the catalytic efficiency of D2HG production is greater in IDH1 R132Q than in R132H mutants for IDH brain tumours. Expression of IDH1 R132Q in cellular and mouse xenograft models leads to higher D2HG levels in cells, tumours and sera compared to R132H-expressing models. #Neuroscience #IDH doi: https://lnkd.in/eWuVi95s https://lnkd.in/e2uZFHTE

Our axoCells™ Astrocytes line (ax0704) is designed to fuel robust in vitro models for neurodegenerative disease research and drug discovery. With labs around the world increasingly moving to in vitro models, drug discovery researchers are embracing human iPSC-derived cells to build more human, more functional models for neuroscience. But with many labs still using rat astrocytes for their work (with very long protocols, some even >100 days), we're "supporting the switch" to human iPSCs with our axoCells Astrocytes product that can drive faster, cheaper in vitro workflows. Key highlights of our axoCells Astrocytes product include: • Best price on the market • Derived from fibroblasts taken from a healthy 40-50-year-old male donor • Assay ready in just 48 hours • Express seven key markers of primary human astrocytes including GFAP, AQP4 and S100B and astrocyte-associated markers (EAAT1 and ALDH1L1) with low levels of neuronal progenitor markers including Nestin • Specifically developed for use in powerful in vitro monoculture models and complex co-culture systems for drug discovery Click here to read more about this product line and how you can use axoCells Astrocytes to power robust, physiologically relevant models of Alzheimer’s Disease, Parkinson’s Disease and ALS: https://hubs.la/Q02H3-SF0 Want to explore the details and get a quote? Click here: https://hubs.la/Q02H3Rb_0 #iPSCs #Astrocytes #AlzheimersDisease #ParkinsonsDisease #ALS #DrugDiscovery

Join host Jo Anne Stratton for the next Killam Seminar Series, given by Iain Clark, Assistant Professor of Bioengineering at University of California, Berkeley. His lab recently developed two novel approaches to study astrocyte-microglia interactions at the single-cell level during inflammation: 1) an in vivo barcoding-based strategy that analyzes the transcriptomes and connections between individual cells, and 2) a droplet-based platform for genome-wide, unbiased CRISPR/Cas9 screening of genes that mediate cell crosstalk. In this seminar, he will discuss the development of these technologies and their application to study astrocyte-microglia signaling in experimental autoimmune encephalomyelitis (EAE), a preclinical mouse model of MS. 📅 Feb. 20 from 4-5 p.m. https://lnkd.in/ewhGiGat #neuroscience #MS #multiplesclerosis #bioengineering